Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience
Posted inNeurology news Pathology & Lab Medicine

Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience

This study demonstrates that the mismatch between tau burden and clinical symptoms identifies individuals with non-AD copathology or cognitive resilience. These findings offer a precision medicine framework for predicting disease trajectories and monitoring responses to emerging anti-amyloid therapies.
Elevated Cardiac Biomarkers Serve as Early Indicators of Structural Brain Damage and Cognitive Decline: Insights from the Hamburg City Health Study
Posted inCardiology Neurology news

Elevated Cardiac Biomarkers Serve as Early Indicators of Structural Brain Damage and Cognitive Decline: Insights from the Hamburg City Health Study

The Hamburg City Health Study reveals that elevated NT-proBNP and hs-cTnI are significantly linked to neurodegeneration and vascular brain injury. These cardiac biomarkers offer a non-invasive pathway for identifying patients at high risk for cognitive impairment and structural brain changes.
Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial
Posted inCardiology Clinical Updates Neurology news Respiratory

Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial

The DANFLU-2 trial demonstrates that high-dose influenza vaccine provides superior protection against influenza-related hospitalizations in chronic kidney disease and reduces cardiorespiratory hospitalizations in older adults irrespective of cardiovascular disease status.
Antiviral Therapy Fails to Slow Alzheimer’s: The VALAD Trial Reveals Unexpected Cognitive Worsening with Valacyclovir
Posted inNeurology news Psychiatry

Antiviral Therapy Fails to Slow Alzheimer’s: The VALAD Trial Reveals Unexpected Cognitive Worsening with Valacyclovir

The VALAD randomized clinical trial found that valacyclovir did not improve outcomes in patients with early symptomatic Alzheimer’s and HSV seropositivity. Instead, patients receiving the antiviral showed significantly greater cognitive decline compared to placebo over 78 weeks, cautioning against off-label use.
The Earlier, the Better: INTERACT Pooled Analysis Confirms 3-Hour Golden Window for Intensive Blood Pressure Lowering in Acute ICH
Posted inEmergency Medicine Neurology news

The Earlier, the Better: INTERACT Pooled Analysis Confirms 3-Hour Golden Window for Intensive Blood Pressure Lowering in Acute ICH

A pooled analysis of over 11,000 patients from the INTERACT trials demonstrates that intensive blood pressure reduction significantly improves functional recovery in acute intracerebral hemorrhage, with the most robust benefits observed when treatment is initiated within three hours of symptom onset.
Telemedicine is Superior to Onboard Neurologists for Optimizing Mobile Stroke Unit Efficiency: Results from the MSU-TELEMED Trial
Posted inEmergency Medicine Neurology news

Telemedicine is Superior to Onboard Neurologists for Optimizing Mobile Stroke Unit Efficiency: Results from the MSU-TELEMED Trial

The MSU-TELEMED trial demonstrates that a telemedicine model for mobile stroke units significantly improves neurologist resource utilization while maintaining safety, outperforming the traditional onboard neurologist model in a hierarchical composite outcome despite a minor four-minute treatment decision delay.
Home-Based Gamma tACS Improves Cognitive Function and Daily Living in Alzheimer Disease: Results from a Randomized Clinical Trial
Posted inNeurology news

Home-Based Gamma tACS Improves Cognitive Function and Daily Living in Alzheimer Disease: Results from a Randomized Clinical Trial

A randomized clinical trial demonstrates that home-based gamma transcranial alternating current stimulation (tACS) over the precuneus safely improves cognitive outcomes and activities of daily living in patients with prodromal and mild Alzheimer disease, supported by neurophysiological evidence of brain engagement.